Liu, H., Wang, Y., Su, T., Shen, N., Zheng, B., Wu, B., Liao, Z., Lu, J., Chang, X., Zhao, J., Li, M., Meng, Q., Shen, S., Ni, X., Zhang, S. (2026). A phase II, exploratory trial of cadonilimab (AK104) plus gemcitabine-cisplatin (GC) as a conversion therapy for patients (pts) with unresectable or systemic treatment–failed biliary tract cancer (BTC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16177